Morgan Stanley Maintains Equal-Weight on GoodRx Holdings, Lowers Price Target to $4
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and lowers the price target from $5 to $4.
Morgan Stanley analyst Craig Hettenbach maintains GoodRx Holdings (NASDAQ:GDRX) with a Equal-Weight and lowers the price target from $5 to $4.